LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Fedratinib | 0.37 | uM | LJP5 | 2 | L04 | 72 | hr | 2543 | 5211 | 5761 | 0.9045 | 0.8368 |
| SK-BR-3 | Fedratinib | 0.37 | uM | LJP5 | 3 | L04 | 72 | hr | 2543 | 5931 | 5760 | 1.0295 | 1.0500 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 1 | L03 | 72 | hr | 2543 | 5233 | 5734 | 0.9126 | 0.8499 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 2 | L03 | 72 | hr | 2543 | 5149 | 5761 | 0.8937 | 0.8183 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 3 | L03 | 72 | hr | 2543 | 5208 | 5760 | 0.9040 | 0.8360 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 1 | L02 | 72 | hr | 2543 | 4187 | 5734 | 0.7301 | 0.5296 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 2 | L02 | 72 | hr | 2543 | 4469 | 5761 | 0.7757 | 0.6125 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 3 | L02 | 72 | hr | 2543 | 4285 | 5760 | 0.7438 | 0.5562 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 1 | L01 | 72 | hr | 2543 | 1528 | 5734 | 0.2665 | -0.3524 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 2 | L01 | 72 | hr | 2543 | 1751 | 5761 | 0.3039 | -0.2713 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 3 | L01 | 72 | hr | 2543 | 1650 | 5760 | 0.2864 | -0.3071 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 1 | P24 | 72 | hr | 2543 | 3405 | 5734 | 0.5938 | 0.2824 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 2 | P24 | 72 | hr | 2543 | 3447 | 5761 | 0.5983 | 0.2939 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 3 | P24 | 72 | hr | 2543 | 4204 | 5760 | 0.7298 | 0.5312 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 1 | P23 | 72 | hr | 2543 | 4183 | 5734 | 0.7294 | 0.5283 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 2 | P23 | 72 | hr | 2543 | 4020 | 5761 | 0.6977 | 0.4741 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 3 | P23 | 72 | hr | 2543 | 4417 | 5760 | 0.7667 | 0.5967 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 1 | P22 | 72 | hr | 2543 | 3875 | 5734 | 0.6757 | 0.4319 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 2 | P22 | 72 | hr | 2543 | 3879 | 5761 | 0.6733 | 0.4302 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 3 | P22 | 72 | hr | 2543 | 4277 | 5760 | 0.7424 | 0.5537 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 1 | P21 | 72 | hr | 2543 | 4118 | 5734 | 0.7181 | 0.5081 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 2 | P21 | 72 | hr | 2543 | 4183 | 5761 | 0.7260 | 0.5246 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 3 | P21 | 72 | hr | 2543 | 4513 | 5760 | 0.7834 | 0.6261 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 1 | P20 | 72 | hr | 2543 | 4277 | 5734 | 0.7458 | 0.5576 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 2 | P20 | 72 | hr | 2543 | 4240 | 5761 | 0.7359 | 0.5422 |